$IGC $HLYK just checked two of the hottest boxes: AI + healthcare automation. A 24/7 autonomous medical agent that streamlines scheduling, insurance verification, and patient engagement solves a real problem—not just a buzzword.
If management converts this into physician adoption and recurring revenue, this could be a major growth catalyst. Keep an eye on volume—strong buying could turn today’s headline into tomorrow’s momentum. 🚀
$AI $TDOC $NVDA
https://finance.yahoo.com/healthcare/articles/healthlynked-launches-ai-powered-healthcare-120000260.html
$HLYK: Scalable AI Healthcare Platform Through Innovation, Partnerships, Population Health, and Cost Optimization
https://richardacavalli.wixsite.com/greenplanetmicrocaps/hlyk-ai-monitization
$HLYK Featured Scalable AI Healthcare Platform Through Innovation, Partnerships, Population Health, and Cost Optimization
https://richardacavalli.wixsite.com/greenplanetmicrocaps/hlyk-ai-monitization
$HLYK HealthLynked (HLYK: OTC is positioning itself at the intersection of artificial intelligence, healthcare coordination, and value-based care—targeting one of the most persistent structural inefficiencies in U.S. healthcare: fragmented communication between patients, providers, and payers.
https://richardacavalli.wixsite.com/greenplanetmicrocaps/hlyk-ai-monitization
$HLYK $NEO $AMZN
Been holding $HLYK since 2019. Started with over 800k shares pre-split under $.05 — now sitting around 8k shares with a much higher average near $5.50 after the reverse split.
Yeah, the dilution and cash concerns are real, but I’m still holding because this isn’t just a tiny clinic company anymore. HLYK is building a healthcare AI/data ecosystem with telemedicine, patient integration, ARi AI, and expanding partnerships.
The market only sees the struggles. I see a micro-cap trying to evolve into a scalable digital healthcare platform. If management secures funding and finally monetizes the tech, the upside from these levels could be enormous due to the tiny market cap.
High risk, yes — that’s why I’m here
Despite the dilution, reverse split, and survival concerns, the article confirms $HLYK is still fighting to transform itself into an AI-driven digital healthcare platform — and if they execute, the upside from these beaten-down levels could be enormous.
$HLYK Excellent article that nails exactly where HLYK stands right now. So if you want to update your HLYK knowledge or get acquainted with HLYK, this is a must read. https://everyticker.com/quote/HLYK/analysis/healthlynked-s-digital-hail-mary-a-micro-cap-s-race-against-time-and-capital-otc-hlyk
$HLYK
Gordo, my previous responses dont seem to be appearing. Yes, I have noticed the recent increase in shareprice. Here is what investors (esp those with relatively large number of shares) should be aware of:
The daily VOLUME is usually quite low (a few thousand at best and sometimes less than that). The BID is usually MUCH lower than the actual shareprice (as I type this it is $1.X LESS than the current shareprice). And the block required is usually MANY times the daily volume (yesterday it was 30K and today it is over 100K). So, even if you wanted to sell only 1000 shares, you would need a collective number of buyers of many MORE thousands. A sell order would usually hang for days/weeks and/or reduce in value to complete.
I dont mention this to be a "basher"; I have experienced this before with similar OTC stocks. Your excitement of the "rise" in shareprice should be tempered, imo.
$HLYK @Lambrusco
Calling it “not an AI play” misses the point. Nobody is saying HLYK is an OpenAI-level AI company—it’s about AI-enabled workflow layered into a healthcare turnaround with a low-float setup.
High risk, sure. But that’s exactly where fast repricing comes from if execution even starts to stick.
And you don’t know me or Uncle Dent
$HLYK Bull case for HealthLynked:
Tiny float, tiny market cap, huge healthcare AI angle. HealthLynked is shifting toward a cloud-based healthcare network focused on connecting patients, doctors, and medical data while incorporating AI tools. The company has also highlighted plans around digital healthcare expansion and a potential Nasdaq uplisting, which could put it on more investors’ radar if executed successfully.
Bullish punch:
HLYK is the definition of a high-risk, high-reward lottery ticket — a micro-cap healthcare AI play with a tiny share count, digital health ambitions, and Nasdaq aspirations. If management executes and gains traction, it wouldn’t take much buying pressure to send this thing moving fast. 🚀
$GNS $HLYK $STUB $NEO
Good luck everyone in your investments. These are mine with my fun money, separate from my Nationwide Pro account and FRS pension.
$GNS 10k shares average $.2741
* Arbitration win: 7.4M shares returned + $8M cash
* 2026 outlook: $20–$22M revenue, potential positive adjusted EBITDA
* AI education expansion + “Space Capsule” rollout
$STUB (StubHub) 3k shares average $6.25
* Q1 2026 earnings scheduled for May 13, 2026 (after close)
* Expanding globally in Asia and Latin America
$NEO (NeoGenomics) 3k shares $7.97
* Raised 2026 revenue guidance to ~$797–$803M
* New cancer test (RaDaR ST MRD) targeting large market
* New insurance coverage boosting demand
$HLYK (HealthLynked) 8k shares $5.54
* Working toward NASDAQ listing via $7M offering
* Launching AI healthcare assistant (ARi) for patient management
Just sharing what I’m personally positioned in—nothing more.
$HLYK
NASDAQ uplisting is the main rocket here. They already filed a $7M offering targeting a NASDAQ move, and recent proxy filings suggest key approvals are coming. Stock already running shows the market is front-running bigger exchange exposure and new buyers.
$DCGO
DocGo officially exploring strategic alternatives is Wall Street code for buyout, merger, or major deal. Add raised 2026 revenue guidance and improving margins, and this looks like a cheap healthcare asset getting noticed. If they clear $1 compliance, momentum can hit fast.
$STUB
StubHub looks beaten down but loaded with upside. FTC settlement clears a major cloud, analysts see huge undervaluation, and profitability is expected this year. The Live Nation monopoly lawsuit could open more market share for rivals like StubHub, giving them a cleaner lane to grow and compete.
That’s my portfolio—three asymmetric plays with catalysts, where patience and positioning now could turn into serious money later.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Valuation
Trading at 3.6× sales vs its 5.1× historical median P/S.
Fair value ≈ $5.05 · price $3.58 today
Undervalued · 29% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
